This content is machine translated MASH Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges? Two drug therapy options—semaglutide (s.c.) and resmetirom (oral)—are now approved in the EU and the U.S. for the treatment of MASH. This is a major breakthrough, especially since, for a...…
View Post 6 min This content is machine translated MASLD/MASH: lifestyle, pharmacotherapy, bariatric procedures Addressing metabolic drivers and counteracting fibrosis Steatotic liver diseases that are not associated with alcohol consumption are now referred to as metabolic steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). There is now no need...…
View Post 15 min This content is machine translated MASH and heart health The underestimated cardiovascular threat Metabolic-associated steatohepatitis (MASH) was long considered a purely hepatic problem. Today, data from large clinical trials and registries clearly show that cardiovascular disease is the most common cause of death...…
View Post 6 min This content is machine translated MASLD often goes unnoticed and is underestimated Think tank for improving the supply situation Metabolic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), can lead to serious complications. Non-invasive diagnostics and AI-supported screening have the potential to facilitate early detection in...…
View Post 6 min This content is machine translated MASLD/MASH Drug therapy options on the rise: spectacular evidence Over the last few decades, the incidence of steatotic liver disease has risen in parallel with the increase in obesity, diabetes and other metabolic diseases. It is recommended to screen...…
View Post 7 min This content is machine translated Steatotic liver disease GLP-1RA in MASH – what’s new? Metabolic dysfunction-associated steatohepatitis (MASH) corresponds tothe liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no...…
